TRIO

Across TCGA pan-cancer cohorts, TRIO RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated TRIO data layer compared with 10 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher TRIO RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRIO expression acts as an unfavorable survival marker, although some lineages such as UCS and ESCA show a favorable association.

MESO, UCS, and ACC are the cancer types where TRIO RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Tertile	All	0.251	0.471	<.001	105	view →
UCS	OS	Tertile	III,IV	0.622	0.106	<.001	90	view →
ACC	DFS	Median	All	0.404	0.757	<.001	83	view →
CESC	DFS	Tertile	III,IV	0.255	0.839	.004	58	view →
UVM	DFS	Tertile	All	0.287	0.833	<.001	57	view →
UCEC	OS	Tertile	All	0.661	0.818	<.001	56	view →
LGG	DFS	Median	All	0.779	0.885	<.001	52	view →
THCA	OS	Quartile	All	0.899	1.000	.003	43	view →
LIHC	DFS	Tertile	All	0.434	0.618	<.001	42	view →
BLCA	DFS	Quartile	All	0.210	0.668	<.001	37	view →
KICH	DFS	Tertile	II,III,IV	0.690	1.000	.009	37	view →
ESCA	OS	Median	II,III,IV	0.671	0.437	.005	29	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

TRIO–MESO (DFS)

Open the MESO breakdown →